Medication verification company Mint Solutions gets $6M; FDA releases additional medical device standards;

@FierceMedDev: We're looking for the fiercest companies in med tech for our 2014 Fierce 15 awards. More details here | Follow @FierceMedDev

@StacyALawrence: Zimmer, Biomet hit regulatory speedbump in pending merger. Story | Follow @StacyALawrence

@VarunSaxena2: JAMA study adds to robotic surgery safety concerns. Article | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: laid out its new strategic plan for developing therapies for rare childhood diseases. PMLiVE article | Follow @EmilyWFierce

> Mint Solutions, maker of patient medication verification device MedEye, raised €4.425 million ($6 million) in a Series A funding round. The funding was co-led by investment firms Life Sciences Partner and Seventure Partners. Story

> FDA is further tightening medical device standards by adding an additional 30 regulations to its "List of Recognized Standards." See the updated list or Read the story

> Doctors urge patients to take labels on medical devices seriously to avoid injury and death after a 74-year-old asthmatic man's inhaler was found lodged in his chest. Story

> Transcatheter aortic valve replacements might have more uses than currently available, according to a JAMA study on Edwards Lifesciences ($EW) and Medtronic ($MDT) heart valve devices. Story

Biotech News

@FierceBiotech: Wall Street wonders what Shire is worth. Report | Follow @FierceBiotech

@JohnCFierce: Merck vet steps in to lead Third Rock's immuno-oncology upstart. Item | Follow @JohnCFierce

@DamianFierce: and DMD docs are upbeat on 144-week eteplirsen data, but shares are down about 10%. Article | Follow @DamianFierce

@EmilyMFierce: Faculty calls for removal of Scripps' leader amid USC merger talks. FierceBiotech Research story | Follow @EmilyMFierce

> Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development. Report

> Regado slips again as FDA weighs in on halted cardio trial. News

> Regeneron, Sanofi herald a blockbuster contender with groundbreaking study. Article

> Bristol-Myers races to the FDA with immuno-oncology star nivolumab. Story

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid--again. Story | Follow @CarlyHFierce

> Pharmacist's theft of $5.6M worth of oxycodone is sure to escalate backlash. News

> NICE likes Lundbeck's alcohol-addiction drug Selincro. Article

> Insurers balk at pricey generic version of ancient GSK heart drug. Story

Vaccines News

> U.S. bioterror readiness highlighted after NIH smallpox discovery. Article

> Could soaring vaccine prices spark Sovaldi-style payer pushback? Story

> No link between Merck's Gardasil and blood clots, study says. Item

> Report: Manufacturing, logistical challenges to weigh down cancer vaccine market through 2022. More

> Canada gives GSK 30-day deadline for turnaround plans at FluLaval plant. Article

Pharma Manufacturing News

> Report: Dendreon's costly manufacturing casts doubt on cancer vax viability. Article

> Portfolio trimming by generics manufacturers linked to soaring drug costs. Item

> Global CMOs tipped to enter Russia as local drug production deadline nears. Story

> Serum Institute allies with biotech in bid to cut cost of biosimilar production. More

> India faces higher QC costs as Shasun shows value of compliance. Article

> U.K. commits cash to $24.7M industry-focused formulation center. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.